How has been the historical performance of Jagsonpal Pharma?

Answer:The historical performance of Jagsonpal Pharma shows significant growth in various financial metrics over the years.

Breakdown:
Jagsonpal Pharma's net sales increased from 158.57 Cr in Mar'20 to 268.72 Cr in Mar'25, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 166.83 Cr in Mar'19 to 268.72 Cr in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 11.06 Cr in Mar'20 to 59.26 Cr in Mar'25, with an operating profit margin that improved from 5.38% to 19.0% during the same period. Profit before tax surged from 9.00 Cr in Mar'19 to 69.86 Cr in Mar'25, while profit after tax reached 55.36 Cr, up from 7.22 Cr in Mar'19. The earnings per share (EPS) increased from 2.76 in Mar'19 to 8.34 in Mar'25, indicating enhanced shareholder value. On the balance sheet, total assets grew from 146.95 Cr in Mar'20 to 278.26 Cr in Mar'25, with total liabilities also rising from 146.95 Cr to 278.26 Cr, but the company maintained a debt-free status throughout this period. Cash flow from operating activities improved significantly, reaching 55.00 Cr in Mar'25, while cash and cash equivalents at the end of Mar'25 stood at 11.00 Cr, showing a stable liquidity position. Overall, Jagsonpal Pharma has demonstrated robust growth and profitability over the years.